ライフサイエンスコーパス: neurokinin

1 mulation of receptors with neurally released neurokinins.

2 ey were significantly less likely to express neurokinins.

3 d activation of the G alpha(q)-coupled human neurokinin 1 (hNK-1) receptor coexpressed with the WT-hN

4 3) receptor antagonist, dexamethasone, and a neurokinin 1 (NK(1)) receptor antagonist.

5 ion between the G protein-coupled tachykinin neurokinin 1 (NK(1)) receptor, expressed in an inducible

6 d with selective antagonists of 5-HT(2A) and neurokinin 1 (NK-1) receptors.

7 key step for efficient synthesis of a potent neurokinin 1 (NK1 ) antagonist in 60 % overall yield.

8 s) via seven-transmembrane G protein-coupled neurokinin 1 (NK1) and NK2 receptors.

9 nerve fibers and activation of its receptor neurokinin 1 (NK1) are important effectors in the transm

10 he neuropeptide substance P (SP) and cognate neurokinin 1 (NK1) nociceptor in PC activation and angio

11 substance P (SP) and its principal receptor neurokinin 1 (NK1) play a specific role in the behaviora

12 gic (Sendide) or non-peptidergic (L703, 606) neurokinin 1 (NK1) receptor antagonist in one masseter m

13 Lamina I neurokinin 1 (NK1) receptor expressing (NK1R(+)) dorsal

14 Lamina I and III neurokinin 1 (NK1) receptor expressing (NK1R+) dorsal ho

15 We also looked for evidence of neurokinin 1 (NK1) receptor internalization in the dorsa

16 compared ERK1/2 activation by the wild-type neurokinin 1 (NK1) receptor with a chimeric NK1 receptor

17 m intracellular stores through its preferred neurokinin 1 (NK1) receptor, thus inducing NO production

18 Almost all neurokinin 1 (NK1) receptor-positive neurons in lamina I

19 ensin II type 1a (AT1a), vasopressin V2, and neurokinin 1 (NK1) receptors are seven-transmembrane rec

20 The effect is blocked by preincubation with neurokinin 1 (NK1; L-732138, 10 mum) and NK3 (SB222200,

21 use of the oral combination of netupitant (a neurokinin 1 [NK1] receptor antagonist) and palonosetron

22 The results also showed neurokinin 1 and not neurokinin 2 as the relevant recept

23 E-1) in controlling substance P (SP) and the neurokinin 1 receptor (NK(1)R) in endosomes of myenteric

24 In chronic pain, the substance P (SP) neurokinin 1 receptor (NK(1)R) redistributes from the pl

25 atory cytokines and of the substance P (SP), neurokinin 1 receptor (NK-1R) in the proximal mesenteric

26 e P (SP), a neuropeptide, interacts with the neurokinin 1 receptor (NK-1R) on immune cells to help co

27 Substance P engages the T cell neurokinin 1 receptor (NK-1R) to enhance IFN-gamma produ

28 SP engages neurokinin 1 receptor (NK-1R) to stimulate cells.

29 fizer), that blocks the binding of SP to the neurokinin 1 receptor (NK-1R).

30 stance P and microinjection of a substance P-neurokinin 1 receptor (NK1-R) antagonist into the NTS at

31 led an increase of the substance P-inducible neurokinin 1 receptor (NK1-R) in the retina of first, th

32 a interaction with its cognate receptor, the neurokinin 1 receptor (NK1-R), is produced by monocyte/m

33 We have investigated the effect of neurokinin 1 receptor (NK1R) agonists on HEK293 cells tr

34 h neurons in laminae III-IV that express the neurokinin 1 receptor (NK1r) and have dendrites that ent

35 ance P (SP) and hemokinin-1 (HK-1), bind the neurokinin 1 receptor (NK1R) and promote stimulatory imm

36 in the pre-Botzinger complex (pre-BotC), the neurokinin 1 receptor (NK1R) and somatostatin (Sst) pept

37 A subset of preBotzinger Complex (preBotC) neurokinin 1 receptor (NK1R) and somatostatin peptide (S

38 Activation of the substance P (SP)/neurokinin 1 receptor (NK1R) axis triggers biliary damag

39 Genetic deletion or antagonism of the neurokinin 1 receptor (NK1R) decreases alcohol intake, a

40 Genetic deletion of the neurokinin 1 receptor (NK1R) has been shown to decrease

41 Neurokinin 1 receptor (NK1R) has key regulating function

42 SP) induces endocytosis and recycling of the neurokinin 1 receptor (NK1R) in endothelial cells and sp

43 Genome editing of the neurokinin 1 receptor (NK1R) in the VTA renders morphine

44 d by spinal opiates; however, when they used neurokinin 1 receptor (NK1R) internalization as an indic

45 Two naturally occurring variants of the neurokinin 1 receptor (NK1R) mediate the effects of SP:

46 stance P (SP) induces the association of the neurokinin 1 receptor (NK1R) with two classes of protein

47 The neurokinin 1 receptor (NK1R), a G protein-coupled recept

48 We investigated the role of the neurokinin 1 receptor (NK1R), a mediator of behavioral s

49 ith those in laminae III-IV that express the neurokinin 1 receptor (NK1r), form a major route through

50 dulator substance P (SP) and its target, the neurokinin 1 receptor (NK1R), in the generation and regu

51 mina III projection neurons that possess the neurokinin 1 receptor (NK1r).

52 tacts with projection neurons expressing the neurokinin 1 receptor (NK1R).

53 nctions by binding with high affinity to the neurokinin 1 receptor (NK1R).

54 and immunological activity via high-affinity neurokinin 1 receptor (NK1R).

55 ypothesize substance P and its receptor, the neurokinin 1 receptor (NK1R; official name TACR1), play

56 s in the nucleus ambiguus also expressed the neurokinin 1 receptor and were labeled retrogradely from

57 VP release from HNS explants, but neither a neurokinin 1 receptor antagonist [L732,138 (N-acetyl-L-t

58 not evident when cells were treated with the neurokinin 1 receptor antagonist aprepitant before SP st

59 sphamide chemotherapy; and the addition of a neurokinin 1 receptor antagonist for adults who receive

60 in wild-type mice, some pretreated with the neurokinin 1 receptor antagonist SR140333.

61 enase inhibitors), pyrilamine, aprepitant (a neurokinin 1 receptor antagonist), or indomethacin with

62 led trials also support an expanded role for neurokinin 1 receptor antagonists in patients who are tr

63 III of the rat spinal cord that express the neurokinin 1 receptor are densely innervated by peptider

64 Finally, we show that the neurokinin 1 receptor for substance P is required for SC

65 wn that blocking substance P (SP) binding to neurokinin 1 receptor with spantide I prevents Pseudomon

66 or 2 additional ICC markers (anoctamin-1 and neurokinin 1 receptor).

67 ibition caused endosomal retention of the SP neurokinin 1 receptor, beta-arrestins, and Src, resultin

68 kinins on platelets are mediated through the neurokinin 1 receptor, which may therefore offer a novel

69 n the monosynaptic C fiber input to lamina I neurokinin 1 receptor-expressing neurons (1-10 Hz stimul

70 (5) pAkt and pmTOR are expressed in neurokinin 1 receptor-positive neurons in laminae I-III

71 We found that when dorsal horn neurokinin 1 receptor-positive neurons or descending ser

72 The neurokinin 1 receptors (NK(1)Rs) and substance P (SP) ha

73 xus (ICC-DMP) of the small intestine express neurokinin 1 receptors (NK1R) and internalize these rece

74 MORs are coexpressed with neurokinin 1 receptors (NK1Rs) in several regions of the

75 ble-stained with antibodies against MORs and neurokinin 1 receptors (NK1Rs) using immunofluorescence.

76 We also found that activation of neurokinin 1 receptors led to SOCE and activation of SOC

77 from neurons expressing mu-opioid receptors, neurokinin 1 receptors, and protein kinase C-gamma.

78 giotensin II receptor type 1 and substance P neurokinin 1 receptors.

79 otC neurons localized by immunoreactivity of neurokinin 1 receptors.

80 ells, which express a combination of a GPCR (Neurokinin 1) and YC3.6.

81 s the neuropeptide substance P (SP) receptor neurokinin 1-R (NK1-R).

82 ity, brain-penetrant, hydroisoindoline-based neurokinin-1 (NK(1)) receptor antagonist with a long cen

83 as to determine the potential involvement of neurokinin-1 (NK(1)) receptors to active vasodilatation.

84 Guidelines recommend use of a neurokinin-1 (NK-1) receptor antagonist in conjunction w

85 retreatment of LAD2 cells with two different neurokinin-1 (NK-1) receptor antagonists and siRNA inhib

86 We also assessed the role of the striatal neurokinin-1 (NK-1) receptor on pre- and post-synaptic M

87 xpression of high affinity receptors for SP (Neurokinin-1 (NK-1) receptors) on microglia and shown th

88 Unilateral intranigral infusions of the neurokinin-1 (NK1) antagonist LY306740 (0 and 50 nmol) b

89 Tac1 and neurokinin-1 (NK1) are involved in autocrine stimulation

90 mission of pain and inflammation through the neurokinin-1 (NK1) receptor, a G protein-coupled recepto

91 with delta selectivity and as antagonist for neurokinin-1 (NK1) receptors were designed and synthesiz

92 possibly suggestive of an internalization of neurokinin-1 (NK1) receptors, which are highly specific

93 er ear; however, its high affinity receptor, neurokinin-1 (NK1), has not been identified and the phys

94 In conclusion, neurokinin-1 and dopamine D1 receptors are required for

95 tifunctional ligands with opioid agonist and neurokinin-1 antagonist activities can be accomplished a

96 In fact, aprepitant - the first neurokinin-1 antagonist approved by the US Food and Drug

97 ervations, the allodynia was unaffected by a neurokinin-1 antagonist.

98 Neurokinin-1 antagonists compete with substance P, an en

99 Neurokinin-1 antagonists have demonstrated superior anti

100 tic stimuli and clinical trials confirm that neurokinin-1 antagonists have significantly higher effic

101 developments involving antiemetics, such as neurokinin-1 antagonists, corticosteroids, dopamine anta

102 In the water hydrogen bond network the neurokinin-1 has a unique Glu residue instead of the hig

103 period as brief as 30s also produced DVs in neurokinin-1 immunoreactive RVM neurons.

104 mmunoexpression of Substance P in week 8 and neurokinin-1 in weeks 8 and 12 in the superficial lamina

105 nalogue, but not significantly by tachykinin neurokinin-1 or neurokinin-2 receptor-selective agonists

106 uman colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R) in response to SP s

107 alternative, nonapoptotic pcd induced by the neurokinin-1 receptor (NK(1)R) activated by its ligand S

108 SP) induces endocytosis and recycling of the neurokinin-1 receptor (NK(1)R).

109 mmation via binding to the G-protein-coupled neurokinin-1 receptor (NK-1R) and release of proinflamma

110 Substance P (SP) and the neurokinin-1 receptor (NK-1R) are involved in the develo

111 Substance P (SP) activation of the neurokinin-1 receptor (NK-1R) contributes to cardiac fib

112 The substance P (SP)-preferring receptor neurokinin-1 receptor (NK-1R) has two forms: a full-leng

113 SP acts by stimulating the neurokinin-1 receptor (NK-1R) on T lymphocytes and other

114 We have shown that substance P (SP) and its neurokinin-1 receptor (NK-1R) regulate intestinal angiog

115 Substance P (SP) via its neurokinin-1 receptor (NK-1R) regulates several gastroin

116 the hypothesis that substance P (SP) and the neurokinin-1 receptor (NK-1R), both in vitro and in vivo

117 mmation that had been considered mediated by neurokinin-1 receptor (NK-1R), we sought to determine wh

118 ression of the proinflammatory and mitogenic neurokinin-1 receptor (NK-1R).

119 chloride secretion, and inflammation via the neurokinin-1 receptor (NK-1R).

120 were independent of its canonical receptor, neurokinin-1 receptor (NK-1R).

121 logic pathways, mainly via its high-affinity neurokinin-1 receptor (NK-1R).

122 influences immune cell functions through the neurokinin-1 receptor (NK-1R).

123 t express the SP receptor, also known as the neurokinin-1 receptor (NK-1r).

124 euronal nitric oxide synthase (nNOS) and the neurokinin-1 receptor (NK1) have been proposed to be inv

125 The neurokinin-1 receptor (NK1R) has two naturally occurring

126 (MOR/DOR) and antagonist bioactivity at the neurokinin-1 receptor (NK1R) have been designed and synt

127 In saline- and CFA-treated rats, neurokinin-1 receptor (NK1R) immunoreactivity was locali

128 e present study, we examined the role of the neurokinin-1 receptor (NK1R) in the modulation of respir

129 However, 33% of PPG(+) neurons contain neurokinin-1 receptor (NK1R) in the rVRG (126 +/- 12; n

130 Neurokinin-1 receptor (NK1R) mediates down-regulation of

131 We demonstrate neurokinin-1 receptor (NK1R) spinal neurons mediate itch

132 1) are neuropeptides that signal through the neurokinin-1 receptor (NK1R) to promote inflammation.

133 Substance P neuropeptide and its receptor, neurokinin-1 receptor (NK1R), are reported to present on

134 , protease-activated receptor-2 (PAR(2)) and neurokinin-1 receptor (NK1R), results in drastically dif

135 reBotzinger Complex (preBotC) that coexpress neurokinin-1 receptor (NK1R), SST, and sst2a are critica

136 Neurokinin-1 receptor (NK1R)-expressing neurones that ar

137 type 1 immunity through agonistic binding to neurokinin-1 receptor (NK1R).

138 pidly internalized upon interaction with the neurokinin-1 receptor (NK1R).

139 The neurokinin-1 receptor (NK1R; encoded by Tacr1) is expres

140 in trigeminal subnucleus caudalis by NMDA or neurokinin-1 receptor activation, and whether inhibition

141 NMDA or the specific neurokinin-1 receptor agonist [Sar(9),Met(O(2))(11)]-SP

142 Intrastriatal infusion of the neurokinin-1 receptor agonist GR-73632 induced striatal

143 Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondanset

144 compound with delta/micro opioid agonist and neurokinin-1 receptor antagonist activities and with a h

145 can be reduced experimentally by intraductal neurokinin-1 receptor antagonist and clinically by use o

146 med a randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant to reduce sy

147 ogate for stroke volume) was improved in the neurokinin-1 receptor antagonist group during the first

148 Furthermore, in vivo treatment with the neurokinin-1 receptor antagonist in DED mice effectively

149 enal ulceration or oesophagitis, whereas the neurokinin-1 receptor antagonist maropitant citrate is l

150 E(2) synthesis in the presence of a specific neurokinin-1 receptor antagonist or in cells genetically

151 We aimed to assess the neurokinin-1 receptor antagonist rolapitant, in combinat

152 However, the neurokinin-1 receptor antagonist significantly reduced b

153 vival in cecal ligation and puncture sepsis (neurokinin-1 receptor antagonist survival = 79% vs vehic

154 Neurokinin-1 receptor antagonist treatment did not preve

155 Finally, pretreatment with the neurokinin-1 receptor antagonist WIN 51,708 (5mg/kg, ip)

156 vely, relative to controls and the selective neurokinin-1 receptor antagonist WIN-51,708 attenuated t

157 Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in comb

158 his paper will review the characteristics of neurokinin-1 receptor antagonists (NK1-RAs) and the new

159 To review the characteristics of neurokinin-1 receptor antagonists and their potential ro

160 Neurokinin-1 receptor antagonists are effective in reduc

161 Neurokinin-1 receptor antagonists are significantly more

162 Newer antiemetic agents (serotonin and neurokinin-1 receptor antagonists) have increased effica

163 ory to 5-HT3 serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone.

164 who will benefit most from prophylaxis using neurokinin-1 receptor antagonists.

165 These data show that early activation of the neurokinin-1 receptor by substance P decreases sepsis su

166 eraction of substance P with the substance P neurokinin-1 receptor expressed by a variety of immune c

167 e present study, we assessed the role of the neurokinin-1 receptor in the production of striatal 3-ni

168 The neurokinin-1 receptor is expressed by lamina I projectio

169 The neurokinin-1 receptor signals efficiently through Gq, Gs

170 Neurokinin-1 receptor treatment at the initiation of sep

171 ent study examined whether inhibition of the neurokinin-1 receptor with a specific antagonist (CJ-12,

172 prevented by the addition of an SP receptor (neurokinin-1 receptor) antagonist.

173 e formation of DVs by Sub P, implicating the neurokinin-1 receptor, a Gq type of G protein coupled re

174 RVM neurons that were immunoreactive for the neurokinin-1 receptor, but not serotonin.

175 prototypical G protein-coupled receptor, the neurokinin-1 receptor, during its different phases of ce

176 Substance P, the principal ligand for the neurokinin-1 receptor, is a potent proinflammatory media

177 impact of deficiency in SP or its receptor, neurokinin-1 receptor, on wound healing in mouse models.

178 The development of the neurokinin-1 receptor-deficient (NK1R(-/-)) mouse permit

179 e and formed numerous close appositions with neurokinin-1 receptor-ir pre-Botzinger complex neurons.

180 19, the beta(2)-adrenergic receptor, and the neurokinin-1 receptor.

181 sis of a key precursor of antagonists of the neurokinin-1 receptor.

182 Neurokinin-1 receptors (NK1Rs) have been shown to mediat

183 gh-affinity receptors for this neuropeptide (neurokinin-1 receptors [NK-1R]), and we have shown that

184 roduction of NO is modulated by the striatal neurokinin-1 receptors and that this receptor may partic

185 Attaching a single quantum dot to individual neurokinin-1 receptors enabled us to follow with high sp

186 investigating the participation of striatal neurokinin-1 receptors in the methamphetamine (METH)-ind

187 f calcitonin gene-related peptide (CGRP) and neurokinin-1 receptors with CGRP(8-37) and RP67580, resp

188 (SP), acting at 5-HT(2A/2C), 5-HT(4), and/or neurokinin-1 receptors, was required to maintain inspira

189 ng sites and were prevented by inhibition of neurokinin-1 receptors.

190 te, group I metabotropic glutamate receptor, neurokinin-1, and tyrosine receptor kinase receptors.

191 esent study, we investigated the role of the neurokinin-1, dopamine D1 and D2 receptors on the METH-i

192 ith spantide I, an antagonist of SP receptor Neurokinin-1, significantly reduced corneal neovasculari

193 Neurokinin-1-receptor antagonism did not alter pneumonia

194 gimen of ondansetron, dexamethasone, and the neurokinin-1-receptor antagonist casopitant mesylate was

195 Administration of a neurokinin-1-receptor antagonist to block substance P si

196 but was not affected by spantide I. mRNA for neurokinin-1-receptor-1 (NK-1R) was detected in the norm

197 s) in addition to its conventional receptor, neurokinin-1.

198 The results also showed neurokinin 1 and not neurokinin 2 as the relevant receptor.

199 Neurokinin-2 receptor (NK(2)R) binding of [(3)H]-SR48968

200 significantly by tachykinin neurokinin-1 or neurokinin-2 receptor-selective agonists.

201 in-ir (immunoreactive) neurons expressed the neurokinin 3 receptor (NK3R) or nuclear estrogen recepto

202 neurokinin B and its corresponding receptor neurokinin 3 receptor (NK3R).

203 INTERPRETATION: Treatment with a neurokinin 3 receptor antagonist (MLE4901) could be prac

204 trial assessed the effectiveness of an oral neurokinin 3 receptor antagonist (MLE4901) on menopausal

205 agents that have such properties-tachykinin neurokinin 3 receptor antagonists-is proposed as a way o

206 They do not colocalize with the neurokinin 3 receptor that stains a type (or two) of OFF

207 c neuropeptide binding preferentially to the neurokinin 3 receptor.

208 Neurokinin 3 receptors (NK3-Rs) are expressed in the sup

209 agonist LY306740 (0 and 50 nmol) but not the neurokinin-3 (NK3) antagonist SR142801 (0 and 50 nmol) l

210 y neurons by injecting a selective toxin for neurokinin-3 expressing neurons [NK(3)-saporin (SAP)] in

211 ant, two structurally diverse antagonists of neurokinin-3 receptor (NK3), displayed distinct modes of

212 Neurokinin-3 receptor (NK3R) has recently emerged as imp

213 ed that neurokinin B (NKB) and its receptor, neurokinin-3 receptor (NK3R), are essential elements for

214 achykinins or exogenous selective tachykinin neurokinin-3 receptor activation with senktide analogue

215 e were inhibited by the selective tachykinin neurokinin-3 receptor antagonists, SB 223412 or SB 23537

216 disease, although the role of the tachykinin neurokinin-3 receptor has not been elucidated.

217 s mimicked by exogenously applied tachykinin neurokinin-3 receptor-selective agonist, senktide analog

218 These neurons are potentially modulated by neurokinin-3 receptors (NK3Rs) of the tachykinin family

219 onfocal microscopy, we identified tachykinin neurokinin-3 receptors on human bronchial parasympatheti

220 e provide the first evidence that tachykinin neurokinin-3 receptors regulate human bronchial parasymp

221 such as neuropeptides, substance P (SP), and neurokinin A (NK-A), which mediate hematopoietic stimula

222 f neuropeptides, including substance P (SP), neurokinin A (NKA), and neurokinin B (NKB), that are enc

223 Substance P and neurokinin A bind to the reconstituted receptor in a bip

224 Modulation of neurokinin A levels may also be related to the effect of

225 ceptors were able to bind to substance P and neurokinin A ligand with similar affinities; however, th

226 C1 (encoding the tachykinins substance P and neurokinin A) to be strongly activated by LP within the

227 ogues of SP, and the NK-2 endogenous ligand, neurokinin A, and is coupled to the phospholipase C path

228 of neuropeptides including substance P (SP), neurokinin A, and neurokinin B, which are recognized for

229 binding of the three peptides, substance P, neurokinin A, and propionyl[Met(O(2))(11)]SP(7-11), to t

230 , Lys-bradykinin, Lys-(des-Arg9)-bradykinin, neurokinin A, Met-Lys-bradykinin, histatin 8, and a myos

231 Despite its inability to respond to neurokinin A, we found that NK1-betaArr1 expression caus

232 ion and nuclear translocation in response to neurokinin A.

233 gents targeting other receptor sites include neurokinin and neurohormonal modulators, chloride channe

234 ith histamine (pyrilamine or cromolyn), or a neurokinin antagonist (spantide).

235 itors, opioids, cholecystokinin antagonists, neurokinin-antagonists, chloride channel activators, gua

236 The neurokinins are neuropeptides that elicit their effect t

237 Neurokinin B (NKB) and its G-protein-coupled receptor, N

238 Patients with loss-of-function mutation in neurokinin B (NKB) and its receptor show hypogonadotropi

239 Human genetic studies have revealed that neurokinin B (NKB) and its receptor, neurokinin-3 recept

240 determine whether preprodynorphin (Dyn) and neurokinin B (NKB) are coexpressed in Kiss1 neurons in t

241 Neurokinin B (NKB) is a hypothalamic neuropeptide bindin

242 Kisspeptin (Kiss1) and neurokinin B (NKB) neurocircuits are essential for puber

243 Arcuate neurokinin B (NKB) neurons express estrogen receptor-alp

244 derable evidence suggests that dynorphin and neurokinin B (NKB) neurons in the hypothalamic arcuate n

245 ction mutations in the genes encoding either neurokinin B (NKB) or its receptor, NK3 (NK3R), result i

246 procal plots of identical slope when [MePhe7]neurokinin B (NKB) was used as the other competition par

247 ng substance P (SP), neurokinin A (NKA), and neurokinin B (NKB), that are encoded by the tac1 (SP and

248 conservation and physiological functions of neurokinin B (NKB), we identified tachykinin (tac) and t

249 in receptor (KISS1R, formerly called GPR54), neurokinin B (TAC3), and the neurokinin B receptor (TACR

250 micked by NK1 (substance P, 100 nm) and NK3 (neurokinin B [NKB], 100 nm) agonists.

251 te nucleus (ARC) that co-express kisspeptin, neurokinin B and dynorphin (KNDy cells) are essential fo

252 he Tac2 gene, which encodes the neuropeptide neurokinin B and its corresponding receptor neurokinin 3

253 called GPR54), neurokinin B (TAC3), and the neurokinin B receptor (TACR3) result in pubertal failure

254 Neurokinin B signalling is increased in menopausal women

255 thalamic neurons that produce kisspeptin and neurokinin B stimulate GnRH release.

256 cystokinin, pronociceptive Substance P (SP), Neurokinin B, and a late wave of somatostatin.

257 Neurokinin B, encoded by the tachykinin3 gene, plays a c

258 ncluding substance P (SP), neurokinin A, and neurokinin B, which are recognized for their roles in th

259 er activity of genes encoding kisspeptin and neurokinin B.

260 arked alterations in hypothalamic kisspeptin/neurokinin B/dynorphin (KNDy) neurons, we hypothesized t

261 are also effects at the ARH to disrupt Kiss1/neurokinin B/dynorphin neuronal function through inhibit

262 We demonstrate that a "neuropeptide," neurokinin-B (NK-B), reversibly inhibits endothelial cel

263 hich encodes proneurokinin-B, a precursor of neurokinin-B (NK-B).

264 ative feedback interactions mediated through neurokinin-B and dynorphin signaling respectively are co

265 second fish putative peptide, referred to as neurokinin F (NKF), is unique and found to be conserved

266 Neurokinins function through G protein-coupled transmemb

267 wide variety of human physiology through the neurokinin G protein-coupled receptor family, implicated

268 ysis showed that piscine Tac3s and mammalian neurokinin genes arise from one lineage.

269 utamate transporters (VGlut2 and VGlut3) and neurokinin I receptors were found in distinct regions of

270 el pathways specifically activated by either neurokinin I, corticotropin-releasing factor receptor 1,

271 s tachykinin receptor 86C (also known as the neurokinin K receptor of D. melanogaster), now has been

272 tive sensory fibers and hemopoietic cells in neurokinin-mediated inflammation and suggest that such s

273 found a significant peripheral component in neurokinin NK-receptor mediated emesis, the authors unde

274 ce-based targets for antipsychotic agents: a neurokinin (NK(3)) antagonist (SR142801), a serotonin 2A

275 The current experiments examined whether neurokinin (NK) 1 and 2 receptors are involved in the ac

276 Neurokinin (NK) 1 receptors and CaV2.3 calcium channels

277 SP activates neurokinin (NK) receptors, which excites midbrain dopami

278 Results demonstrated that neurokinin (NK1 and NK2) antagonists blocked the inducti

279 ent SAP conjugate to target NTS neurons with neurokinin (NK1) receptors.

280 agonize muscarinic M3, alpha2 adrenergic and neurokinin NK2 receptors, respectively.

281 lanocortin, melatonin, muscarinic M1 and M3, neurokinin, opioid KOP and serotonin receptors.

282 Neurokinins (or tachykinins) are peptides that modulate

283 ultiple inflammatory mediators, specifically neurokinins, prostanoids, and histamine.

284 rved following intravenous pretreatment with neurokinin receptor antagonists (3+/-7% relaxations).

285 icular administration (20 nmol h(-1)) of the neurokinin receptor antagonists CP99994 or SB223412.

286 the design of new therapeutics targeting the neurokinin receptor family.

287 t cholinergic interneuron activation through neurokinin receptor stimulation.

288 c endothelial cells differentially expressed neurokinin receptor subtypes.

289 gonadotropin-releasing hormone antagonists, neurokinin receptor-1 antagonists), but available inform

290 n the efflux of cAMP from exocrine cells and neurokinin receptors are important in substance P-mediat

291 otein-coupled receptors and the study of the neurokinin receptors in particular.

292 The present experiments examined the role of neurokinin receptors in this learning deficit.

293 Erythroid cells did not express neurokinin receptors, whereas aortic and yolk sac endoth

294 suggest that ICC-DMP are primary targets for neurokinins released from enteric motor neurones in the

295 Our study describes a mechanism for neurokinin signaling in sensory neurons and provides evi

296 ate an interaction between the nicotinic and neurokinin signaling systems that may form the basis for

297 pha5-containing nAChRs and depends on intact neurokinin signaling.

298 Here we target the neurokinin system, which is involved in both pain and ad

299 R and DOPR similarly attenuates the DNIC and neurokinin type 1 receptor internalization induced eithe

300 s measured in the spinal cord by visualizing neurokinin type 1 receptor internalization.